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BACKGROUND Due to deliverability and thrombogenicity concerns,
efforts are being made to decrease the strut thickness of the bio-
resorbable stents without compromising radial strength and dura-
bility. This study aimed to evaluate the scaffold expansion of the
novel sirolimus-eluting scaffolds with 120mm and 150mm strut thick-
ness (AMA-120 or -150, Amaranth Medical, Mountain View, CA),
compared to Absorb BVS using previously described (TCT2014)
methods.
METHODS A total of 125 scaffolds (32 AMA-120; 46 AMA-150 and 47
Absorb) were implanted (stent-to-artery ratio: 1.1:1) in coronary ar-
teries of 51 healthy swine. Angiography and OCT imaging were per-
formed at post-implant, 28-day and 90-day follow up. Minimum
balloon diameter (MBD) of the last inﬂated balloon at the highest
pressure and minimum stent diameter (MSD) immediately after the
last balloon deﬂation were assessed by QCA. % Acute Recoil (AR) was
deﬁned as (MBD-MSD)/MBDx100%. Projected Diameter (PD) was
deﬁned as the stent diameter to be achieved per compliance chart at
the pressure used. Accordingly, % Under-expansion (in vivo stent
response to arterial elastic forces regardless of “native” recoil) was
deﬁned as (PD-MBD)/PDx100%. Total Stent Deﬁcit is the sum of the %
under-expansion and % AR ¼ (PD-MSD)/PDx100% (FIGURE). Addi-
tionally, % Late Recoil (LR) was examined by OCT and deﬁned as
(inner scaffold area at post-procedure – inner scaffold area at follow-
up)/ inner scaffold area at post-procedure.
RESULTS The results are summarized in the TABLE. There was no
signiﬁcant difference in % AR between AMA-120, AMA-150 and
Absorb. %Under-expansion of AMA-150 was slightly higher than
AMA-120 and similar to Absorb. Consequently, Total Stent Deﬁcit
showed the same trend as the under-expansion. The % LR in AMA
BVS groups was less or similar to that in Absorb BVS at 28 days and 90
days.AMA 120 AMA 150 Absorb BVS P ValueQCA %ACUTE RECOIL 1%8% 2%8% 3%7% 0.32%UNDERXPANSION 2%7% 6%7% 7%9% 0.04
TOTAL STENT
DEFICIT3%8% 8%9% 10%7% 0.001OCT % Late Recoil (DAY
28)-2%8% 3%4% 7%7% 0.02% Late Recoil (DAY
90)-1%7% -5%15% 3%11% 0.17CONCLUSIONS The novel 120mm sirolimus-eluting bioresorbable
scaffold demonstrated acute and chronic radial strength in vivo
equivalent or better than its regular-thickness counterpart or Absorb
BVS.
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BACKGROUND Long-term follow-up of bioresorbable scaffolds evi-
denced vascular dimensional restoration, in contrast to the vascular
caging characteristic in permanent metallic stents (BMS). We aim to
evaluate the chronic, in vivo, vascular changes following the coronary
implantation of a novel non-drug eluting, magnesium-based, bio-
resorbable scaffold (MBRS).
METHODS Six stents (MBRS¼3 vs BMS¼3) were implanted (1.1:1 B:A
ratio by angiography) in RCA of juvenile swine and evaluated by OCT
at baseline, 1, 2 and 3 months. Morphometry was assessed at every
time point in stented and reference segments.
RESULTS The non-stented reference segments demonstrated a pro-
gressive increase in lumen area (1 month¼8.01.0mm2, 2
months¼10.52.0 mm2, 3 months¼10.71.9 mm2) that was aligned
with the mean growth of the animal (1 month¼ 39kg, 2 months¼
47kgs, 3 months¼ 58kgs). As expected, there was no geometrical
changes in the BMS stents. BMS did not display modiﬁcations in their
stent area (6.00.3 mm2, at each time point) or lumen area (1 and 2
months¼5.60.4mm2, 3 months¼ 6.00.6 mm2) with a consistent
neointimal obstruction (1 and 2 months¼0.10.1%, 3 month-
s¼0.00.1%). In contrast, MBRS showed a gradually progressive in-
crease in stent area from 1 month (5.80.5 mm2) to a >30% increase at
3 months (7.62.2 mm2) and an additional 30% at 3 months
(10.32.5 mm2). Importantly is to note that at three month the stent
area in MBRS (10.32.5 mm2) is exactly the same as the reference
segment (10.71.9 mm2). In parallel, the luminal area increase
accordingly (1 month¼4.40.6 mm2, 2 months¼6.52.1, 3
months¼8.21.5 mm2). The neointimal obstruction observed in MBRS
remained constantly minimal (1 month¼0.20.1%, 2 month-
s¼0.20.0%, 3 months¼0.20.1%).
CONCLUSIONS In this preliminary experimental study, the novel
bare magnesium-based bioresorbable stent was associated with
dimensional restoration and vascular adaptability to remodel outward
to match the physiological and dimension requirements of the coro-
nary artery without excessive neointimal proliferation in contrast
with the encaged coronary treated with BMS.
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BACKGROUND The safety and efﬁcacy of the Absorb (Abbott) bio-
resorbable vascular scaffold (BVS) has been documented in lower-risk
patient and lesion subsets with “real-world” outcome data being
scarce. Here we report the experience gathered with the BVS primarily
in daily practice at a high-volume Dutch center.
METHODS Between July 2009 – January 2015, 297 patients (330 le-
sions) were treated with BVS. Registry data collection is ongoing and
gathered prospectively in-hospital, at 1 and 6 months and then yearly
up to 5 years.
RESULTS Mean follow-up time was 323 days (median 236 days) with
44% of patients having at least 1 year of follow-up. Clinical presen-
tation of pts. (73% male, mean age 59 years, 16% diabetes, 25% with
previous PCI and/or CABG) was ACS in 55%. Lesion complexity was
